Skin & hair

The TNF Blockers and Where They Still Fit

Save

For years, a TNF inhibitor was the only kind of biologic a dermatologist could offer for psoriasis that wasn't controlled by creams or light treatment. That's no longer true — IL-17 and IL-23 inhibitors have joined the options — but TNF inhibitors haven't disappeared from the conversation, particularly for people managing joint symptoms alongside their skin. Here is how this drug class works, where it sits in the current treatment ladder, and who it still makes the most sense for.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

What TNF Inhibitors Are and How They Work

TNF inhibitors are a class of biologic drugs — adalimumab, etanercept, infliximab, and certolizumab pegol are the ones used in psoriasis — that work by binding and neutralizing tumor necrosis factor-alpha, an inflammatory signaling protein that drives much of the skin inflammation in psoriasis 1. TNF-alpha (tumor necrosis factor-alpha) is the inflammatory signal this drug class blocks, rather than suppressing the immune system broadly. TNF inhibitors were the first biologic class approved for psoriasis, and the clinical-trial evidence behind them, along with years of real-world use, is part of why they remain a well-understood, well-characterized option even as newer drug classes have entered the field 1. Depending on the specific drug, a TNF inhibitor is given as a self-injection at home on a regular schedule or as an infusion in a clinic, and dosing and monitoring recommendations differ by agent — which is one more factor, alongside efficacy, that goes into choosing among the four options within this class rather than treating them as interchangeable 1.

Where TNF Inhibitors Sit on the Psoriasis Treatment Ladder

TNF inhibitors generally enter the conversation after topical treatment hasn't been enough on its own. Topical corticosteroids are the mainstay for limited, non-intertriginous plaques, with vitamin D analogs and other steroid-sparing agents used to reduce how much steroid a person needs over time 2. Phototherapy — narrowband or broadband UVB, PUVA, or excimer laser — is often the next step for more widespread disease that isn't responding to topicals alone, and narrowband uvb phototherapy what to expect over a full course remains a reasonable option before or alongside a biologic for many people 3. TNF inhibitors and other biologics come into play when topical treatment and phototherapy together haven't controlled the disease, or when psoriasis is severe or extensive enough from the start that starting there doesn't make sense 1.

Why TNF Inhibitors Still Matter Alongside Newer Biologics

IL-17 and IL-23 inhibitors have since produced some of the clearest skin results in the biologic class overall, and for people focused purely on how much a treatment clears the skin, those newer options often come up first in the conversation. TNF inhibitors haven't been pushed out of use, though, and one of the clearest reasons is psoriatic arthritis: for people with active psoriatic arthritis, guidelines conditionally favor a TNF-inhibitor biologic over oral small-molecule drugs as a first-line choice, ahead of several other biologic classes 4. TNF inhibitors remain the biologic class with the strongest first-line evidence for people who have both psoriasis and active psoriatic arthritis. That keeps them squarely in the conversation for the substantial share of psoriasis patients who also have joint disease, where a drug that treats both skin and joints from one prescription is a real advantage over choosing separately.

TNF Inhibitors Beyond Psoriasis Itself

Adalimumab's reach extends well beyond psoriasis: adalimumab for hidradenitis suppurativa became the first biologic ever approved specifically for that separate inflammatory skin disease, also driven substantially by TNF-alpha 5. That range says something about the pathway itself — TNF-alpha turns out to matter across more than one inflammatory skin condition — but it also means a clinician managing someone with more than one TNF-driven condition at once sometimes has a practical reason to reach for this class specifically, rather than treating each condition with a separate, narrower drug. Someone with psoriasis, psoriatic arthritis, and a third TNF-driven condition all at once is a more common combination than it might sound, given how much these inflammatory diseases cluster together, and it's exactly the kind of overlapping picture where one well-chosen biologic doing more than one job has a real practical advantage over layering separate prescriptions.

Screening for What Else Might Be Going On

Because psoriasis clusters with several other conditions, guidelines recommend actively screening for psoriatic arthritis, cardiovascular disease, metabolic syndrome, and psychiatric comorbidity such as depression and anxiety, rather than treating the skin in isolation 6. None of this changes which biologic gets chosen by itself, but it shapes the fuller picture a clinician is weighing alongside skin clearance, and it's part of why a psoriasis visit sometimes includes questions that seem to have little to do with the skin in front of them. A joint that's been stiff or swollen, a mood that's been low, or a waistline and blood pressure that have crept up are all reasonable things to mention at a dermatology visit even if nobody asks directly, since catching psoriatic arthritis early is part of the same reasoning that makes a TNF inhibitor attractive for some patients in the first place.

What Starting a TNF Inhibitor Involves

Before starting any biologic in this class, standard practice includes screening for infections such as tuberculosis and hepatitis, since TNF inhibitors work by tempering part of the immune system's response to inflammation, with monitoring continuing at intervals through treatment 1. Response is usually judged at a defined point rather than day to day, and not everyone who starts a TNF inhibitor reaches the level of clearance they're hoping for — which is the scenario where a different biologic class becomes the next reasonable conversation rather than simply stopping treatment altogether.

When a Different Biologic Class Makes More Sense

Psoriasis biologics compared side by side today show more nuance than newer simply being better: il-17 biologics for psoriasis often post strong skin-clearance numbers, IL-23 inhibitors offer some of the least frequent dosing schedules, and TNF inhibitors carry the deepest track record alongside the strongest psoriatic arthritis evidence 1. What decides which biologic you get in practice usually comes down to joint involvement, other health conditions, a dosing schedule someone can realistically stick with, and how an individual has responded to biologics tried before. None of that makes TNF inhibitors obsolete; it makes them one well-established branch of a decision that now has several reasonable branches to choose from.

Common questions

They're still used. Newer IL-17 and IL-23 inhibitors have matched or exceeded TNF inhibitors on skin clearance for many people, but TNF inhibitors remain a leading choice for psoriasis alongside active psoriatic arthritis, and they carry the longest track record of real-world use of any biologic class for this disease.

Psoriatic arthritis is the clearest reason — TNF inhibitors are conditionally preferred as a first-line biologic for active joint disease. Cost, insurance coverage, dosing schedule, and how someone has responded to biologics before also factor into the decision, alongside how a person's skin and joints respond over time.

Yes. Adalimumab, for example, is also approved for hidradenitis suppurativa, a separate inflammatory skin disease, as well as for psoriatic arthritis. The same inflammatory pathway, TNF-alpha, contributes to more than one condition, which is part of why this drug class has such a wide range of approvals.

Standard practice includes screening for infections such as tuberculosis and hepatitis, since this drug class works by tempering part of the immune response. Monitoring continues at intervals through treatment, and response is usually assessed at a defined checkpoint rather than day to day.

Not everyone reaches the level of clearance they're hoping for on a given biologic, TNF inhibitors included. Switching to a different biologic class, such as an IL-17 or IL-23 inhibitor, is a common next step rather than assuming biologics in general won't work.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When to Contact a Prescriber While on a TNF Inhibitor

  • —Signs of infection — fever, persistent cough, or a wound that isn't healing — while on a TNF inhibitor
  • —New or worsening joint pain and swelling that wasn't present before
  • —Unexplained bruising, bleeding, or persistent fatigue
  • —Any sign of a serious allergic reaction after an injection or infusion

Signs of a serious infection or a severe allergic reaction after a dose warrant prompt medical attention — urgent care, or the ER if symptoms are severe or rapidly worsening.

This article is general health information, not medical advice. It cannot tell you whether a TNF inhibitor is the right choice for your psoriasis or replace an in-person evaluation. Decisions about starting, continuing, or switching a biologic should be made with the dermatologist or rheumatologist managing your care.

References

  1. 1.American Academy of Dermatology; National Psoriasis Foundation (2019). Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology. PMID 30772098 ✓AAD-NPF recommendations for treating psoriasis with biologic agents including TNF inhibitors (adalimumab, etanercept, infliximab, certolizumab pegol), covering efficacy, dosing, and safety monitoring, and supporting the biologic tier of the psoriasis treatment ladder.
  2. 2.American Academy of Dermatology; National Psoriasis Foundation (2021). Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. Journal of the American Academy of Dermatology. PMID 32738429 ✓AAD-NPF recommendations for topical treatment of psoriasis: topical corticosteroids for non-intertriginous plaques and steroid-sparing agents (vitamin D analogs, tazarotene, calcineurin inhibitors) — supports the first-line topical step of the psoriasis treatment ladder.
  3. 3.American Academy of Dermatology; National Psoriasis Foundation (2019). Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with phototherapy. Journal of the American Academy of Dermatology. PMID 31351884 ✓AAD-NPF recommendations on phototherapy for psoriasis (narrowband/broadband UVB, PUVA, excimer laser), supporting the phototherapy tier of the psoriasis treatment ladder before or alongside biologic therapy.
  4. 4.Singh JA, Guyatt G, Ogdie A, et al. (2019). 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Care & Research / Arthritis & Rheumatology. PMID 30499246 ✓ACR/NPF guideline conditionally recommending TNF-inhibitor biologics over oral small-molecule drugs as first-line therapy for active psoriatic arthritis, ahead of other biologic classes.
  5. 5.Kimball AB, Okun MM, Williams DA, et al. (2016). Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. New England Journal of Medicine. doi:10.1056/NEJMoa1504370The PIONEER I and II phase 3 trials formed the basis for adalimumab's approval as the first biologic indicated for hidradenitis suppurativa — used here to show TNF inhibitors' approval range beyond psoriasis.
  6. 6.American Academy of Dermatology; National Psoriasis Foundation (2019). Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. Journal of the American Academy of Dermatology. PMID 30772097 ✓AAD-NPF guideline recommending screening for psoriatic arthritis, cardiovascular disease, metabolic syndrome, and psychiatric comorbidity in people with psoriasis.

6 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — citations link their sources. Editorial policy

← Back to the health library